Umeki S, Adachi M, Watanabe M, Yaji S, Soejima R
Department of Medicine, Kawasaki Medical School, Okayama, Japan.
Arch Intern Med. 1988 Jun;148(6):1409-12.
The effects of gabexate mesilate on disseminated intravascular coagulation (DIC) accompanying neoplastic diseases or severe infections in ten patients were investigated and compared with those of heparin therapy in ten other patients with DIC. Of 11 patients with DIC (control) who did not receive any anticoagulation therapy for DIC, ten died of pneumonia, DIC secondary to the underlying diseases, or pulmonary edema. Heparin therapy was effective in five patients (50%), while treatment with gabexate was successful in seven patients (70%). Although the therapeutic efficacy of gabexate was not significantly different from that of heparin, in patients in whom bleeding tendencies were observed at the start of the therapy, the former was successful in four (80%) of five patients, while the latter was effective in only one (25%) of four patients treated. The results of this preliminary and nonrandomized study suggest that gabexate is as effective as heparin for the treatment of DIC, and that it may be more successful than heparin in the treatment of DIC accompanied by bleeding diathesis.
研究了甲磺酸加贝酯对10例伴有肿瘤性疾病或严重感染的弥散性血管内凝血(DIC)患者的影响,并与另外10例DIC患者的肝素治疗效果进行了比较。11例未接受任何针对DIC的抗凝治疗的DIC患者(对照组)中,10例死于肺炎、基础疾病继发的DIC或肺水肿。肝素治疗使5例患者(50%)有效,而加贝酯治疗使7例患者(70%)成功。虽然加贝酯的治疗效果与肝素无显著差异,但在治疗开始时观察到有出血倾向的患者中,前者在5例患者中有4例(80%)成功,而后者在4例接受治疗的患者中仅1例(25%)有效。这项初步的非随机研究结果表明,加贝酯在治疗DIC方面与肝素一样有效,并且在治疗伴有出血素质的DIC方面可能比肝素更成功。